


Addressing the “Diabetesity” epidemic

Discover the Tema Cardiovascular and Metabolic ETF, which seeks to provide long-term growth by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases.

Capital at risk



Cardiovascular Diseases

#1 cause of death¹

Over 80% of patients with coronary heart disease (CHD) are overweight or obese⁴

Diabetes doubles the risk of cardiovascular disease⁵

The “Diabetesity” crisis is at a breaking point

Obesity

42%¹ of US adults are obese²


Obesity is the leading risk factor for type-2 diabetes⁶

Diabetes

Half a billion adults affected globally³


Sources: 1Our world in data, 2019. 2Obese defined as BMI greater than 30. 3CDC. 4Prev Med. 2017 Nov; 104: 117–119, “Obesity in Coronary Heart Disease: An Unaddressed Behavioral Risk Factor”, Philip A. Ades, MD and Patrick D. Savage, MS. 5American Heart Association. 6Tex Heart Inst J. 2011; 38(2):142–144 “The Epidemic of Obesity and Diabetes”, Ann Smith Barnes, MD, MPH. See Glossary in appendix for full definitions.

Cardiovascular disease spend forecast to crest \$1 trillion annually




Source: LHS – World Economic Forum and the Harvard School of Public Health. “The Global Economic Burden of Non-communicable Diseases”, 2011. Bloom, D.E., Cafiero, E.T., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L.R., Fathima, S., Feigl, A.B., Gaziano, T., Mowafi, M., Pandya, A., Prettnner, K., Rosenberg, L., Seligman, B., Stein, A.Z., & Weinstein, C. (2011). RHS – IQVIA Forecast Link, May 2023. Forecasts are inherently limited and should not be relied upon when making investment decisions. There is no guarantee projected growth will occur.

The obesity epidemic is getting worse: 42% of US adults are obese




Sources: CDC; Prevalence of Self-Reported Obesity Among U.S. Adults by State and Territory, BRFSS, 2011 and 2021.

Recent breakthroughs in obesity therapeutics are a watershed moment



Source: Google Search Trends for “Ozempic”, Worldwide ; 1STAT/Harris Poll survey “Obesity and Weight Loss Meds.: Attitudes and Interest”. Ozempic is an off-label use for obesity, which is FDA approved for Type II diabetes but not for obesity. A similar drug, high dose semaglutide, or Wegovy, was approved for obesity in 2021.


Continual innovation in weight loss keeps pushing the boundary, especially in combination agents




Source: Stifel, healthcare, “Obesity drug review”, market update July 1st, 2023. Some of the companies highlighted in this slide are holdings of the Tema Cardiovascular and Metabolic ETF portfolio. For a list of current fund holdings, please visit the fund web page at www.temaetfs.com/hrts.

Examples of metabolic and cardiovascular innovations


Effect of GLP-1 on the human body



New continuous glucose monitoring devices have empowered diabetes patients



Why now?
Worst biotech downcycle in decades,
nearly 29% of small biotech trade below net cash value¹




Source: Bloomberg. S&P Biotechnology Select Industry Index (comprises stocks in the S&P Total Market Index that are classified in the GICS biotechnology sub-industry) used for 2008, 2015, 2021 cycles. Cycles start dates are defined by index price peaks for each year. Nasdaq Biotech Index (contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria) used for 2001 cycle. Past performance is not indicative of future results. ¹Bloomberg as of October 2023, biotech defined by GICS definition of the biotechnology sub-industry, small cap defined by North American companies under \$2 billion mkt cap. The referenced index is shown for informational purposes only and is not meant to represent the Fund. You cannot invest directly in an index. The measures are representative of the indexes underlying holdings and are not indicative of future performance.

Vibrant universe of approved and pipeline obesity drugs calls for active management approach



Source: Stifel, healthcare, “Obesity drug review”, market update July 1st, 2023. Some of the companies highlighted in this slide are holdings of the Tema Cardiovascular and Metabolic ETF portfolio. For a list of current fund holdings, please visit the fund web page at www.temaetfs.com/hrts.

Tema HRTS ETF portfolio:
balanced across key technologies and company profiles



Source: Tema HRTS ETF Portfolio as of 11/21/2023, subject to change. Tema classification based on main business and company drivers. Risk profile is subjective categorization by Tema. Established refers to maturing growth businesses with a long-term history of profitable operations. Growth businesses refer to recently commercialized companies or companies in early stages of rapid growth from a material product cycle, with not yet at scale profit margins. Emerging Biopharma refer to pre-revenue companies. For a full list of fund holdings [click here](#).



Click here to download
HRTS's Investor Deck

[Download Deck](#)

Addressing the metabolic and heart disease epidemic Tema Cardiovascular and Metabolic ETF (HRTS)

The actively managed Tema Cardiovascular and Metabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against diabetes, obesity and cardiovascular diseases.


Five reasons to consider HRTS ETF



Underpenetrated, Large Market


Obesity is forecast to affect one in four people globally by 2035, and obesity-related conditions like diabetes and heart disease represent vast markets with significant growth potential.

Source: World Obesity Atlas, March 2023.




Innovation

The Industry is witnessing significant progress in obesity therapeutics led by new drugs such as Ozempic and Wegovy, as well as a renaissance in cardiovascular therapies through novel platforms like gene editing.




Research expertise

The fund conducts deep and comprehensive research, in an effort to identify those companies that deliver breakthrough solutions at attractive valuations.



Barriers to Entry

In our view, many of the businesses identified have high barriers to entry, such as costly and lengthy clinical trials, large salesforce requirements in primary care markets, and substantial patent protection.




Uncorrelated

Performance of many companies relies on clinical or commercial success, which is an uncorrelated source of return.


HRTS portfolio breakdown

Country weighting



- Japan
- United States
- Britain
- Switzerland
- Denmark
- Germany
- Ireland

Market cap bands (\$bn)



- 0-1
- 1-2
- 2-5
- 5-10
- 10-50
- >50

Information and data as of 11/21/2023 and subject to change. Figures may not add up to 100% due to rounding. For a full list of fund holdings [click here](#).

Click here to learn more
about HRTS's portfolio

[About HRTS](#)



Join our newsletter and receive
more insightful multimedia content

[Subscribe](#)



Risk Information

Carefully consider the Fund's investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund's prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com. Read the prospectus carefully before investing

Investing involves risk including possible loss of principal. There is no guarantee the adviser's investment strategy will be successful.

Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.

Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.

Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company's valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable. Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.

Investing in Foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.

Tema Global Limited serves as the investment adviser to Tema Cardiovascular and Metabolic ETF (the "Fund"), and NEOS Investments, LLC serves as a sub adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA's BrokerCheck.

For inquiries: info@temaetfs.com

